ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech's proprietary technology.
“We are very happy to have commenced this collaboration. Genzyme is a world leader at developing treatments for rare genetic diseases”
Both companies will collaborate over the next 15 months to perform feasibility studies with encapsulating the enzyme and testing the new formulation in preclinical studies. Genzyme has an option to enter into a broader licensing agreement for development and commercialization of this product. Other terms of the deal were not disclosed.
"We are pleased to work with ERYtech Pharma. Their technology is uniquely suited to deliver therapeutic enzymes that could benefit patients with a number of genetic diseases" said Seng Cheng, Genzyme Vice President, Genetic Diseases Science.
"We are very happy to have commenced this collaboration. Genzyme is a world leader at developing treatments for rare genetic diseases," said Yann Godfrin, CEO and CSO of ERYtech Pharma. "They will bring us tremendous expertise in this field. We hope this collaboration will provide an opportunity to improve the lives of patients with this enzyme deficiency. It will also be a strong demonstration of the utility of our technology for other therapeutic enzymes and disease indications such as chronic metabolic diseases. This collaboration complements very well other preexisting R&D agreements and demonstrates our scientific leadership to advance our technologic platform."
Gut enzyme discovery sheds light on bilirubin balance in humans